Houston, Texas--(Newsfile Corp. - May 19, 2020) - Psychedelics may soon alter the way we address mental and health issues.
That may be especially true when it comes to treating obesity, which has been recognized by the World Health Organization as a global epidemic, with at least 2.8 million people dying each year as a result. In addition, according to the World Health Organization, more than 1.9 billion adults, 18 years and older, are overweight. Of these over 650 million are obese.
Those are startling statistics. However, there may be a psychedelic solution.
Psilocybin Could Help Solve that Global Obesity Epidemic
One of the key psychedelics that may assist with treating obesity are psilocybin mushrooms, which can also assist with issues such as PTSD, depression, anxiety, obsessive compulsive disorder, and even chronic pain.
Even Johns Hopkins Medicine's Center for Psychedelic and Consciousness Research, for example, is focusing on psychedelics, including psilocybin for the treatment of eating disorders.
Companies like Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) subsidiary NeonMind Biosciences Inc. are also nearing studies to confirm that is an effective treatment for weight loss and food craving. The goal of this study is to use preclinical models to confirm that psilocybin is an effective treatment for weight loss and food craving.
NeonMind will use models that have been widely adopted by the pharmaceutical industry to identify compounds with therapeutic efficacy. It plans to use results from this study as part of the requirements for a Health Canada clinical trial application to demonstrate potential efficacy and safety for novel compounds.
NeoMind Biosciences Ltd. Files U.S. for Patent
NeonMind also filed a U.S. provisional patent application to protect intellectual property relating to the use of compounds found in psychedelic mushrooms to lose weight.
NeonMind's pending patent includes the use of psilocybin to help with weight loss, reduce food cravings, counter compulsive eating, improve quality of diet, increase metabolism, treat diabetes, regulate blood glucose levels, and help reduce susceptibility to cardiovascular disease, high blood pressure, and other issues associated with diabetes.
The company hopes to tap into multi-billion-dollar market opportunities, including the $245 billion weight loss and management market, $64 billion cardiovascular disease treatments, the $156 billion depression market, and the $87 billion diabetes treatment market.
For more information, visit the company's website at .
About MarijuanaStox
is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with , is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please for full disclaimer.
Contact Information:
2818047972
To view the source version of this press release, please visit
